Breadcrumb

[A19-95] Avelumab (renal cell carcinoma) - Benefit assessment according to §35a Social Code Book V

Overview

Overview

Commission: Commission awarded on 2019-11-21 by the Federal Joint Committee (G-BA)
Status:Commission completed
Department/Division:Drug Assessment
Current document:PDF Extract of dossier assessment  [PDF, 104 kB] (German version) Further documents
Note:

After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.

Contact address:to the contact form
Linked projects: [G20-06] Avelumab (renal cell carcinoma) - Addendum to Commission A19-95
Status: Commission completed

[G17-09] Avelumab (metastatic Merkel cell carcinoma) - Benefit assessment according to §35a (1), Sentence 11, Social Code Book V
Status: Commission completed

[A20-41] Avelumab (renal cell carcinoma) - Addendum to Commission A19-95
Status: Commission completed

[A20-34] Avelumab (metastatic Merkel cell carcinoma) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed


Report documents

Report documents

PublishedDocumentSizeType 
2020-03-02 Extract of dossier assessment (German version) 104 kBPDFdownload file
2020-03-02 Dossier assessment (German version) 2 MBPDFdownload file

After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.



Save result list

To save your search result, please copy the link below and paste it into a new tab/window.

close